Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06121843 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 147
- Enrollment target
- 19
- Study locations
NCT06121843: Recruiting Phase 1 study of Multiple Myeloma, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
NCT06121843 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. The registered enrollment target is 147 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% lower). The trial reports 19 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06121843, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 147 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).
Conditions Studied
Interventions
- DRUG Elranatamab
- DRUG Iberdomide
- DRUG BMS-986393
- DRUG Mezigdomide
- DRUG Alnuctamab
Study Locations (19)
New York
- Roswell Park Cancer Institute - Buffalo
- Laura and Isaac Perlmutter Cancer Center - New York
- Local Institution - 0009 - New York
- Memorial Sloan Kettering Cancer Center - New York
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic in Arizona - Phoenix - Phoenix
California
- City of Hope Comprehensive Cancer Center - Duarte
Florida
- Mayo Clinic in Florida - Jacksonville
Georgia
- Northside Hospital - Atlanta
Minnesota
- Mayo Clinic in Rochester, Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2024-02-22 |
| Est. Completion | 2028-08-01 |
| Phase | Phase 1 |
What NCT06121843 shows while recruiting
NCT06121843 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Elranatamab is the first listed.
NCT06121843 lists 19 locations in 15 states (New York, Massachusetts, Alabama).
Frequently Asked Questions
What is clinical trial NCT06121843 about?
NCT06121843 is a clinical study titled "A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma". The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).
What is the current status of trial NCT06121843?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 147 participants. The study started on 2024-02-22. Estimated completion is 2028-08-01.
What conditions does trial NCT06121843 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT06121843?
The interventions under investigation include: Elranatamab (DRUG), Iberdomide (DRUG), BMS-986393 (DRUG), Mezigdomide (DRUG), Alnuctamab (DRUG).
Who is sponsoring clinical trial NCT06121843?
This trial is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06121843 being conducted?
This trial has 19 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06121843's enrollment target sits among peer trials
147 136th of 438 higher than 302 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06184516 · 147 participants · Phase 2
Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI